Amarin Corp. Plc (AMRN)

6.68
0.08 1.18
NASDAQ : Health Technology
Prev Close 6.76
Open 6.90
Day Low/High 6.66 / 7.03
52 Wk Low/High 3.95 / 26.12
Volume 7.76M
Avg Volume 15.17M
Exchange NASDAQ
Shares Outstanding 385.60M
Market Cap 2.40B
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Sirius XM May Have Opened Pandora's Box With Takeover Announcement

Sirius XM May Have Opened Pandora's Box With Takeover Announcement

The satellite radio operator's stock is declining after announcing the purchase of the streaming radio service.

Stocks Wake Up After Hard Selloff

Stocks Wake Up After Hard Selloff

Stock buyers are back after Thursdays selloff helped by Pandora's jump higher. Dell's disaster continues and China has a fat finger trade.

Amarin Stock May Be Worth the Wait

Amarin Stock May Be Worth the Wait

A growing and aging population ensures biotechs won't go out of style.

Futures Rise on Key Earnings

Futures Rise on Key Earnings

US stock futures are rising on strong earnings from DuPont and Coach, while Amarin gets a nod from the FDA - Debra Borchardt gives details.

The Next Big Thing in Biotech: J.P. Morgan Conference

The Next Big Thing in Biotech: J.P. Morgan Conference

Adam Feuerstein, senior columnist for TheStreet, says the coming week's J.P. Morgan Healthcare Conference is the next big thing in biotech.

Amarin rated new Buy at Citigroup

The Next Big Thing in Biotech

The Next Big Thing in Biotech

Adam Feuerstein, senior columnist for TheStreet, says biotech earnings are the next big thing to watch in biotech.

Catch a Ride if You Can

Catch a Ride if You Can

Be willing to chase this rally, even though it's disliked by so many market players.

The Next Big Thing in Biotech: FDA Approvals

The Next Big Thing in Biotech: FDA Approvals

Senior columnist Adam Feuerstein says post-FDA approval trading is the next big thing to watch in biotech.

The Next Big Thing in Biotech: Amarin, Onyx

The Next Big Thing in Biotech: Amarin, Onyx

Adam Feuerstein, senior columnist for TheStreet, says Amarin and Onyx are the next big things in biotech.

3 Stocks I Saw on TV, July 12

3 Stocks I Saw on TV, July 12

Dan Fitzpatrick examines three stocks viewed on Fast Money. Today's stocks include Tibco Software, Arena Pharma, and Church & Dwight.

AZO Could be the Next Shoe to Drop

AZO Could be the Next Shoe to Drop

After AAP and ORLY warn, one has to be very cautious with Autozone.

Trust Level Is Low

Trust Level Is Low

The downtrend isn't over yet, so you might as well knock out some trades in the short term.

Uncertainty Reigns

Uncertainty Reigns

I have little trust, so I'm sticking with small, quick day-trades.

Risk Is High

Risk Is High

But you can deal with it by playing fast and tight.

Renting, Not Buying

Renting, Not Buying

I'm playing the bounce and taking on a few trades.

May, or May Not, Day

May, or May Not, Day

Market strength on May 1 is not necessarily an indication that a rally will follow.

Playing Tight

Playing Tight

If the market retests early lows, all bets are off.

Amarin rated new Buy at Citigroup

The Next Big Thing in Biotech: M&A

The Next Big Thing in Biotech: M&A

Senior columnist Adam Feuerstein says M&A is the next big thing in biotech.

Looking Skittish out There

Looking Skittish out There

I'm not looking to do any major shorting into strength at this point.

Fitz Bits: E*Trade Prepares to Shoot Higher

Fitz Bits: E*Trade Prepares to Shoot Higher

After its recent run, it appears to be headed for its next price target.

Optimism but No Major Action

Optimism but No Major Action

The only big move was a stumble in volatility, but equities failed to take advantage.

A Closer Look at Citigroup and Apple

A Closer Look at Citigroup and Apple

I've reduced my exposure in both of these positions.

Relief Bounce Brewing

But trust levels are very low since we haven't managed to bounce at all the past week.

Two Pharmas Offer High Potential

Two Pharmas Offer High Potential

The sector is seeing strong revenue, and Jazz and Amarin have the charts to match.

The Danger Is Real

As we head into Friday's expiration, the next support level is last week's low.